Results 21 to 30 of about 7,958,059 (273)

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. [PDF]

Am J Clin Dermatol
BackgroundTuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI).
Torres T, Chiricozzi A, Puig L, Lé AM, Marzano AV, Dapavo P, Dauden E, Carrascosa JM, Lazaridou E, Duarte G, Carvalho AVE, Romiti R, Rompoti N, Teixeira L, Abreu M, Ippoliti E, Maronese CA, Llamas-Velasco M, Vilarrasa E, Del Alcázar E, Daponte AI, Papoutsaki M, Carugno A, Bellinato F, Gisondi P.   +24 more
europepmc   +4 more sources

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms. [PDF]

Drugs Context
Background: Psoriasis is a chronic inflammatory condition that may develop into psoriatic arthritis (PsA) in a significant number of patients. Clinical signs such as enthesitis and nail involvement have been suggested as early indicators of this ...
Dattola A, Bernardini N, Anedda J, Atzori L, Bonifati C, Bruni PL, Giordano D, Graceffa D, Molinelli E, Moretta G, Mugheddu C, Offidani A, Pagnanelli G, Pallotta S, Papini M, Persechino S, Richetta AG, Tolino E, Trovato F, Pellacani G, Potenza C.   +20 more
europepmc   +2 more sources

TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors. [PDF]

J Psoriasis Psoriatic Arthritis, 2022
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic therapies are approved. Over the past decade, studies have documented the higher efficacy of IL-17 and IL-23 inhibitors for the treatment of psoriasis compared to the ...
Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, Liao WJ.   +5 more
europepmc   +2 more sources

Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective

Dermatology and Therapy, 2023
Psoriasis vulgaris is a systemic, chronic inflammatory disease affecting 2–3% of the population. Recent advances in the understanding of the pathophysiology of psoriatic disease have facilitated the development of novel therapeutic options with improved ...
Riley K. Spencer, Kareem G. Elhage, Joy Q. Jin, Mitchell S. Davis, Marwa Hakimi, Tina Bhutani, Howard Chang, Wilson Liao   +7 more
doaj   +1 more source

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

The Lancet Regional Health. Europe, 2022
Summary: Background: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis ...
Linda Davidson, Juul M.P.A. van den Reek, Mariolina Bruno, Florence van Hunsel, Ron M.C. Herings, Vasiliki Matzaraki, Collins K. Boahen, Vinod Kumar, Hans M.M. Groenewoud, Frank L. van de Veerdonk, Mihai G. Netea, Elke M.G.J. de Jong, Bart Jan Kullberg   +12 more
doaj   +1 more source

The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans [PDF]

, 2011
IL-23 and Th17 cells are key players in tissue immunosurveillance and are implicated in human immune-mediated diseases. Genome-wide association studies have shown that the IL23R R381Q gene variant protects against psoriasis, Crohn's disease and ...
Di Meglio, P, Chung-Ching Chu, Francesca Capon, Di Meglio, Paola, Napolitano, Luca, Napolitano, L, Ketty Peris, Di Cesare, Antonella, Villanova, Federica, Villanova, F, Richard C. Trembath, Isabella Tosi, Paola Di Meglio, Richard C Trembath, Laggner, Ute, Chu, Chung-Ching, Chu, CC, Capon, Francesca, Federica Villanova, Frank O Nestle, Nestle, FO, Peris, K, Nestle, Frank O., Antonella Di Cesare, Peris, Ketty, Trembath, RC, Laggner, U, Tosi, Isabella, Luca Napolitano, Capon, F, Frank O. Nestle, Ute Laggner, Trembath, Richard C., Di Cesare, A, Tosi, I   +34 more
core   +2 more sources

Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab

Clinical Kidney Journal, 2023
ABSTRACT We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after ...
Stryckers, Marijke, Van Oevelen, Stefaan, Koshy, Priyanka, Sprangers, Ben, Van Craenenbroeck, Amaryllis H.   +4 more
openaire   +4 more sources

Possible role of IL‐23 inhibitor in autoimmune hemolytic anemia

European Journal of Haematology, 2023
AbstractRituximab and prednisone are commonly used treatments for autoimmune hemolytic anemia (AIHA), where the body's immune system attacks and destroys its red blood cells. However, some AIHA patients may become refractory to rituximab treatment, and this can result in continued hemolysis and persistent anemia, making it challenging for affected ...
Naveen Premnath, Urvashi Pandey, Mohak Pandey, K. Venuprasad   +3 more
openaire   +2 more sources

IL-23-mediated ROCK activation promotes Tγδ17 cell migration.

, 2020
(a) IL-7-expanded Tγδ17 cells were stimulated with IL-23 for 6 h in the presence or absence of Y27632 inhibitor or left unstimulated (uns.). Representative histogram shows pSTAT3-Y705 measured by flow cytometry.
Candelas Álvarez-Salamero (8611707), Gloria Pastor-Fernández (8611710), Isabel R. Mariblanca (8611713), Jesús Pino (293477), Raquel Castillo-González (827266), María N. Navarro (8611719), Danay Cibrian (8611716)   +6 more
core   +1 more source

Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis

Pharmaceuticals, 2023
Targeted therapies represent major advancements in the treatment of chronic skin conditions such as psoriasis. While previous studies have shown an increased risk of melanoma and non-melanoma skin cancer (NMSC) in patients receiving TNF-α inhibitors, the
Marta Krzysztofik, Paweł Brzewski, Przemysław Cuber, Artur Kacprzyk, Aleksandra Kulbat, Karolina Richter, Tomasz Wojewoda, Wojciech M. Wysocki   +7 more
doaj   +1 more source